NMR system in Bend Research's R&D facility.
Patel continues, "So prior to bringing the
DFS model together – each entity would be
out there trying to find the situations where
the technology was most relevant. But by
putting them together, the business model is
really driven by being somewhat agnostic to
the choice of technology and extremely data
driven – to pick the most appropriate technology for the task at hand."
Patel goes on to say that Bend Research
brought to Capsugel a set of technologies that
completed the “tool kit” as well as a very deep
experience level in technology screening and
selection that could now be applied to technologies that Capsugel did not have.
“There are not many companies that can
claim the length or breadth of experience in
that bioenhancement suite of technologies
that we have," says Patel. “We have a full
range of capabilities in technologies such as
modified release. Where Bend has a history
of taking other approaches to modified re-
lease, Capsugel has a history of developing
very specific and functional technologies
toward modified release through capsules –
where the capsule itself has characteristics
to enable modified release. And Encap has a
history of using functional coatings.”
By bringing these three historically differ-
ent businesses together, DFS now has a very
comprehensive toolkit that allows them to
not go to market pitching one technology as
Patel says Bend had made a name for
themselves in spray-dried dispersion, hot-
melt extrusion, and nanotechnology. Encap
had a very focused history of liquid and
semi-solid filling, and Capsugel, even before
being spun out from Pfizer, had a very good
background in lipid formulations.
"It’s not even to say – that one is better
A GREAT FIT – BUT WHY?
than another,” says Patel. “The key ques-
tion is which one is appropriate for any
them to solve problems is a cool spot to be
in – we now have this group to do that.”
“A core principle – a building block that
both companies brought – is the equipment
and technology know-how. For example,
no other capsule manufacturer has 100%
inspection technology or the liquid filling/
sealing process we have developed," says
Jim Coward, Capsugel’s Head, Market
Development – Dosage Form Solutions.
The combination of Capsugel, Bend
Research and Encap into the Dosage Form
Solutions group has been, to stretch a
phrase – a win, win, win situation.
One of the primary reasons Capsugel became interested in Bend Research and Encap
Drug Delivery, was Bend’s expertise in bioavailability enhancement, modified and targeted
release technologies, and other specialized
applications such as lipid multi-particulate
technology, inhalation formulation, its abuse
deterrent and taste-masking approaches and
other manufacturing capabilities.
Patel describes the market before the creation of the DFS group, “Prior to the acquisition of Encap and Bend Research into DFS